Abstract 117P
Background
PARP inhibitors are now the standard of care for patients with ovarian cancer. The determination of HRD status has become essential to predict sensitivity to these targeted therapies, and has to be integrated in routine oncology assays, beyond the search for BRCA1/2 pathogenic variants. We present the integration of an HRD assay based on tumor shallow whole genome sequencing (sWGS) fully integrated in an existing NGS workflow dedicated to somatic oncology.
Methods
25 samples from ovarian cancer with HRD status was determined using two CE-IVD assays (5 Sofia Genetics / 20 Myriad Genetics). Samples have been re-analysed, starting from FFPE blocks. We performed new DNA extractions from FFPE blocks followed by our dedicated workflow for solid tumor using NGS sequencing. DNA samples were prepared using hybridation method (Twist BioScience®) with Unique Molecular Identifiers (UMI). Part of libraries from HRD samples were collected before the capture step, and directly pooled for sequencing on Illumina® NextSeq 500. sWGS produced were analysed by a dedicated CE-IVD Bioinformatic pipeline for HRD status determination (SeqOne®).
Results
3 different runs of 10 samples each have been sequenced for replicability evaluation. No failure were encountered on any of the sequenced samples. The mean depth, Q30 quality and duplicate rates for sWGS produced were respectively 1.12X / 88.8% / 1.94%, far above the minimum requirements for analysis (> 0.1X). Replicability analysis show an average variation of 4% of the final HRD score. Regarding the HRD status determination, our results show an agreement of 93.3% with the status previously determined, in line with the results obtained by SeqOne during the validation of their bioinformatic analysis (93%).
Conclusions
Theses results demonstrate innovative integration into routine genetics’s laboratory. This implemented methodology allows us to provide a full report with both BRCA1/BRCA2 variant identification and the HRD status for each patient, in an efficient and cost-effective workflow.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract